Phase 1 Oesophageal Cancer Trial, Recruiting (NCT05984342)

Phase 1 Oesophageal Cancer Trial, Recruiting NCT05984342 Sponsor: Affiliated Cancer Hospital of Shantou University Medical College Condition: Oesophageal Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT05984342 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Oesophageal Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Be between 18 and 70 years old
Have not received any treatment before surgery, such as radiation therapy, chemotherapy, targeted therapy, or immunotherapy
Have been diagnosed through a tissue biopsy with a specific type of esophageal cancer (squamous cell carcinoma) in the chest area, where the cancer has also spread to nearby lymph nodes but not to distant parts of the body
Be scheduled to have surgery to remove the esophagus with the goal of curing the cancer
Be generally well enough to carry out light daily activities (confirm with trial site)
Have no signs that the cancer has come back before starting the additional treatment after surgery
Have normal heart rate and blood pressure readings before joining the trial
Be able to understand what the study involves and have signed a consent form agreeing to take part

Who may not be able to join:

Have had, or currently have, any other type of cancer
Have a lung condition involving scarring or inflammation of the lung tissue
Need to regularly take steroid medications or other medicines that suppress the immune system
Have a known or suspected allergy to chemotherapy drugs or to the study drug Tislelizumab
Have an active condition where the immune system attacks the body (such as lupus or rheumatoid arthritis)
Currently have active hepatitis (liver infection)
Have been assessed by the study doctor as not suitable to take part, for any reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 23 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05984342

Sponsor: Affiliated Cancer Hospital of Shantou University Medical College

Phase: Phase 1

Status: Recruiting

Condition: Oesophageal Cancer

More information: https://clinicaltrials.gov/study/NCT05984342

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

Be between 18 and 70 years old
Have not received any treatment before surgery, such as radiation therapy, chemotherapy, targeted therapy, or immunotherapy
Have been diagnosed through a tissue biopsy with a specific type of esophageal cancer (squamous cell carcinoma) in the chest area, where the cancer has also spread to nearby lymph nodes but not to distant parts of the body
Be scheduled to have surgery to remove the esophagus with the goal of curing the cancer
Be generally well enough to carry out light daily activities (confirm with trial site)
Have no signs that the cancer has come back before starting the additional treatment after surgery
Have normal heart rate and blood pressure readings before joining the trial
Be able to understand what the study involves and have signed a consent form agreeing to take part

Who may not be able to join:

Have had, or currently have, any other type of cancer
Have a lung condition involving scarring or inflammation of the lung tissue
Need to regularly take steroid medications or other medicines that suppress the immune system
Have a known or suspected allergy to chemotherapy drugs or to the study drug Tislelizumab
Have an active condition where the immune system attacks the body (such as lupus or rheumatoid arthritis)
Currently have active hepatitis (liver infection)
Have been assessed by the study doctor as not suitable to take part, for any reason (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 23 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Affiliated Cancer Hospital of Shantou University Medical College

Registry

ClinicalTrials.gov

Start date

2 August 2023

Est. completion

30 June 2025

Where this trial is recruiting

🇨🇳 China

Primary endpoints

disease-free survival rate

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov